MICD

Across TCGA pan-cancer cohorts, MICD RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated MICD data layer.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher MICD RNA is associated with better overall survival. In most high-consensus cancer types, elevated MICD expression acts as an unfavorable survival marker, although some lineages such as PAAD and HNSC show a favorable association.

PAAD, KIRP, and ESCA are the cancer types where MICD RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	II,III,IV	0.703	0.464	<.001	74	view →
KIRP	OS	Median	II,III,IV	0.737	0.955	.003	50	view →
ESCA	DFS	Median	IV	0.205	0.634	.006	36	view →
LIHC	OS	Quartile	All	0.371	0.675	<.001	31	view →
HNSC	DFS	Tertile	IV	0.472	0.283	.006	24	view →
KICH	DFS	Median	II,III,IV	0.431	0.928	.011	17	view →
THYM	DFS	Median	II,III,IV	0.946	0.527	.006	10	view →
THCA	DFS	Median	III,IV	0.848	0.941	.014	7	view →
LUSC	OS	Tertile	All	0.703	0.449	.035	4	view →
COAD	DFS	Median	All	0.748	0.810	.024	4	view →
DLBC	OS	Median	II,III,IV	0.843	1.000	.028	4	view →
STAD	OS	Tertile	II,III,IV	0.763	0.574	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

MICD–PAAD (OS)

Open the PAAD breakdown →